AIM Persistence

Persistence Bio is a biotechnology company focused on developing therapies that target drug-tolerant persister (DTP) cells, which are believed to be a primary cause of cancer recurrence and drug resistance. By identifying the unique metabolic and molecular vulnerabilities of these dormant cells that survive initial treatment, the company aims to develop small molecule inhibitors that can be used in combination with standard-of-care therapies. Their approach seeks to eliminate the minimal residual disease that often leads to relapse in patients with solid tumors. The company's platform integrates advanced screening and biological modeling to discover novel targets specifically expressed in the persister state.